List of Excipients in Branded Drug ADVIL LIQUIGELS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	COCONUT OIL
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	FD&C GREEN NO. 3
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	GELATIN
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	LECITHIN, SOYBEAN
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	POLYETHYLENE GLYCOL
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	POTASSIUM HYDROXIDE
Navajo Manufacturing Company Inc	ADVIL LIQUIGELS	ibuprofen	67751-148	SORBITAN

Advil Liqui-Gels Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Advil Liqui-Gels is an over-the-counter, liquid-filled softgel containing 200 mg ibuprofen. Its commercial value comes from the combination of ibuprofen solubilization, rapid disintegration, swallowability, dose recognition, and strong brand distribution rather than from a currently identifiable market exclusivity period. The principal excipient platform uses polyethylene glycol, potassium hydroxide, sorbitol, gelatin, purified water, lecithin, colorants, and printing materials to create a liquid ibuprofen fill and a consumer-recognizable softgel shell.[1]

The strongest commercial opportunities are lower-cost softgel manufacture, differentiated rapid-release products, preservative-free liquid fills, pediatric and geriatric presentations, combination analgesics, and improved packaging for moisture and oxygen control. New products would need to comply with the FDA’s ibuprofen OTC requirements and avoid relying on Advil trademarks, trade dress, or protected manufacturing know-how.

What excipients are used in Advil Liqui-Gels?

The U.S. Drug Facts label identifies Advil Liqui-Gels as a 200 mg ibuprofen liquid-filled capsule. Public labeling identifies the inactive ingredients as gelatin, polyethylene glycol, potassium hydroxide, purified water, sorbitol, lecithin, FD&C Blue No. 1, and pharmaceutical ink.[1]

Component	Publicly identified role	Commercial relevance
Polyethylene glycol	Liquid vehicle and ibuprofen solubilization medium	Supports a nonaqueous or predominantly nonaqueous fill and manufacturing flexibility
Potassium hydroxide	Alkalinizing agent and ibuprofen salt formation aid	Can improve apparent solubility of the weakly acidic ibuprofen molecule
Sorbitol	Plasticizer or moisture-control component in the softgel system	Affects shell flexibility, brittleness, and long-term appearance
Gelatin	Softgel shell polymer	Controls mechanical strength, dissolution, oxygen and moisture permeability
Purified water	Shell processing and formulation component	Affects gelatin hydration, viscosity, drying, and capsule stability
Lecithin	Wetting, dispersing, or emulsifying aid	Can improve contact between ibuprofen and the fill vehicle
FD&C Blue No. 1	Colorant	Supports product identification and brand differentiation
Pharmaceutical ink	Capsule marking	Enables imprinting, authentication, and product recognition

The precise concentrations, grades, processing parameters, fill viscosity, shell thickness, drying cycle, and manufacturing controls are not disclosed in the consumer label. Those parameters can have greater commercial importance than the ingredient list because they determine leakage, dissolution, fill uniformity, capsule appearance, and shelf life.

Why does polyethylene glycol matter in ibuprofen softgels?

Ibuprofen has limited water solubility. A polyethylene glycol-based liquid fill can provide a practical vehicle for incorporating ibuprofen into a softgel rather than compressing the active into a conventional tablet. Potassium hydroxide can convert a portion of ibuprofen into an ibuprofenate salt or otherwise increase ionization within the fill.

The formulation objective is not simply to dissolve ibuprofen. It is to maintain a stable, pumpable fill that can be encapsulated at high speed, remains compatible with gelatin, and releases the drug consistently after ingestion. Excessive alkalinity, water migration, shell interactions, or changes in fill viscosity can cause leakage, brittleness, delayed dissolution, or capsule deformation.

What is the function of the gelatin shell?

The gelatin shell provides a swallowable, unit-dose container for the liquid formulation. Shell composition and drying conditions affect:

• Mechanical strength during filling, packaging, transport, and consumer handling.
• Moisture migration between the shell and liquid fill.
• Capsule dissolution and rupture.
• Compatibility with colorants, printing inks, and packaging materials.
• Storage stability under elevated temperature and humidity.

A competitor could use a gelatin shell with a different plasticizer system, a vegetarian shell based on hydroxypropyl starch or hydroxypropyl methylcellulose, or a modified gelatin blend. Those changes could create differentiation but would require substantial development work because non-gelatin shells have different oxygen permeability, water activity, sealing behavior, and dissolution profiles.

How does Advil Liqui-Gels compare with ibuprofen tablets and caplets?

Advil Liqui-Gels competes on dosage form and consumer experience rather than on a different active ingredient. Each standard product contains 200 mg ibuprofen, the same strength commonly used in OTC tablets and caplets.[1,2]

Product characteristic	Liquid-filled softgel	Conventional tablet or caplet
Active ingredient	Ibuprofen	Ibuprofen
Standard U.S. dose	200 mg	200 mg
Fill system	Solubilized or dispersed liquid	Compressed solid
Shell or coating	Gelatin-based softgel shell	Tablet coating or uncoated tablet
Consumer positioning	Easy-to-swallow, liquid-filled, premium format	Low-cost, familiar solid dose
Manufacturing economics	Higher shell and encapsulation complexity	Usually lower unit cost at scale
Differentiation	Tactile format, appearance, perceived convenience	Price, count size, retailer availability
Primary technical risk	Leakage, shell-fill interaction, dissolution variability	Compression defects, coating failure, disintegration

Liquid-filled softgels can command a retail premium, but their economics are more sensitive to gelatin, labor, encapsulation throughput, rejects, and packaging requirements. Private-label products can compete by using the same 200 mg strength while reducing branding, packaging, and distribution costs.

What FDA regulatory status applies to Advil Liqui-Gels?

Advil Liqui-Gels is an OTC ibuprofen product regulated under the FDA’s analgesic, antipyretic, and antirheumatic drug framework. Oral ibuprofen at approved OTC strengths is governed by the FDA OTC monograph system and applicable labeling requirements, including directions, warnings, age restrictions, and dosing limitations.[2,3]

The regulatory pathway is materially different from approval of a new prescription drug. A compliant private-label or store-brand ibuprofen softgel generally relies on conformity with the applicable OTC requirements rather than an abbreviated new drug application based on an Advil-branded product. The manufacturer still must establish identity, strength, quality, purity, stability, manufacturing controls, and label compliance.

Is Advil Liqui-Gels listed in the Orange Book?

The FDA Orange Book is principally a database for approved prescription drugs and certain approved over-the-counter drugs that were approved under applications. It is not a complete database of OTC monograph products.[4]

Advil Liqui-Gels should therefore not be treated as having a conventional Orange Book patent listing equivalent to a prescription product with listed patents and pediatric exclusivity. The commercial barrier is primarily regulatory compliance, formulation know-how, trademarks, manufacturing capability, and distribution scale.

What patents protect Advil Liqui-Gels?

The original liquid-filled ibuprofen capsule concept has historically been associated with softgel formulation and encapsulation technology. Earlier patents covering ibuprofen liquid fills, soft gelatin dosage forms, solubilization, and manufacturing processes are likely to be expired or outside their original enforceable terms, given the age of the commercial format.

A current competitor should separate four categories of rights:

1. Active-ingredient rights. Basic ibuprofen composition-of-matter protection is not a current barrier to OTC entry.
2. Formulation rights. Claims may cover solvent systems, ibuprofen salts, concentration ranges, excipient ratios, or dissolution performance.
3. Manufacturing rights. Claims may cover encapsulation, sealing, drying, shell composition, or fill-processing conditions.
4. Brand and trade-dress rights. Advil names, logos, capsule appearance, packaging, and consumer-facing design may create the most immediate commercial risk.

The public Drug Facts label does not disclose a complete patent portfolio or proprietary formulation specification. A reliable freedom-to-operate review must examine live U.S. patents, continuations, terminal disclaimers, assignments, and claim scope in USPTO records. It is not accurate to infer current exclusivity from the existence of the Advil brand or from historical softgel patents.

When does Advil Liqui-Gels lose exclusivity?

Advil Liqui-Gels does not have a single upcoming loss-of-exclusivity date comparable to a prescription drug with one primary patent and one regulatory exclusivity period. Ibuprofen is an established generic active ingredient, and multiple manufacturers can market compliant 200 mg oral ibuprofen products.

Exclusivity category	Advil Liqui-Gels position
Active-ingredient exclusivity	No current practical barrier
Prescription-style Orange Book exclusivity	Not the primary commercial framework
OTC monograph access	Available to compliant manufacturers
Brand exclusivity	Protected through trademarks and unfair-competition law
Formulation exclusivity	Depends on any live, claim-scope-specific patents
Manufacturing exclusivity	Depends on process patents and trade secrets
Retail exclusivity	Driven by contracts, shelf placement, and distribution

The relevant entry question is not when ibuprofen becomes generic. It is whether a competitor can produce a stable, compliant, consumer-acceptable softgel at a cost low enough to compete with Advil and private-label alternatives.

Are there Paragraph IV challenges to Advil Liqui-Gels?

Paragraph IV certification is an ANDA mechanism used to challenge listed patents for approved drug products. It is not the standard entry mechanism for an OTC monograph product that is not relying on an Orange Book-listed prescription drug application.[4,5]

Accordingly, a competitor seeking to market a monograph-compliant ibuprofen softgel would generally focus on FDA OTC compliance, manufacturing validation, labeling, and intellectual-property clearance. A Paragraph IV challenge would become relevant only if a specific approved application and relevant listed patent formed the legal basis for the proposed product.

What formulation patents could protect a competing ibuprofen softgel?

New patent opportunities are more likely to arise from measurable formulation or process improvements than from the general concept of putting ibuprofen in a softgel. Potential claim areas include:

Lower-solvent or solvent-free ibuprofen fills

A formulation that reduces polyethylene glycol content, replaces certain solvents, or uses a novel ibuprofen salt could support patent claims if it delivers a non-obvious improvement in stability, dissolution, manufacturability, or tolerability.

Fast-release liquid fills

A competitor could target rapid capsule rupture and dissolution through:

• Modified ibuprofen particle size.
• Controlled alkalinity.
• Surfactant or wetting-agent optimization.
• Alternative polyethylene glycol grades.
• Reduced fill viscosity.
• Shell designs that control water ingress and rupture.

A claim would be stronger if it ties the excipient composition to a reproducible dissolution or pharmacokinetic result rather than claiming a broad list of conventional ingredients.

Vegetarian and low-allergen shells

Hydroxypropyl methylcellulose and other non-gelatin shells can support consumer differentiation. The technical opportunity is to match gelatin-softgel performance in seal integrity, oxygen protection, dissolution, and high-speed encapsulation.

Abuse-resistant or child-resistant presentations

Although ibuprofen is not generally treated as a controlled substance, packaging innovation can reduce accidental pediatric ingestion. Unit-dose blistering, senior-friendly but child-resistant systems, and dose-limiting packaging may support commercial differentiation without changing the formulation.

What commercial opportunities exist in Advil Liqui-Gels excipients?

The strongest opportunity areas are listed below.

Opportunity	Value proposition	Main development barrier
Private-label liquid-filled ibuprofen	Lower-price alternative to Advil	Cost, scale, retailer qualification
Vegetarian softgel	Appeals to gelatin-avoidant consumers	Shell performance and process validation
Pediatric liquid-filled dose	Swallowability and reduced measuring steps	Age-appropriate dose, safety, and packaging
Geriatric easy-swallow format	May improve administration convenience	Capsule size, labeling, and human factors
Combination analgesic softgel	Adds a second active or symptom target	Drug-drug compatibility and regulatory review
Premium rapid-release product	Differentiates on onset positioning	Requires defensible performance data
Sustainable packaging	Reduces plastic or improves recyclability	Barrier performance and supply-chain cost
Contract manufacturing	Supports brands without softgel capacity	Quality systems and minimum production volume

Which excipients offer the best platform opportunity?

Polyethylene glycol and shell polymers are the most strategically important excipient categories. Polyethylene glycol grades influence fill viscosity, solubilization, pumping, and stability. Gelatin grade, bloom strength, plasticizer ratio, and water content influence encapsulation performance and shelf life.

Lecithin and related wetting agents can support lower-viscosity or higher-load formulations, but they may introduce oxidation, odor, or compatibility issues. Potassium hydroxide can improve solubilization but narrows the formulation window because alkalinity can affect chemical stability, shell compatibility, and consumer tolerability.

A supplier with pharmaceutical-grade polyethylene glycol, gelatin, shell polymers, or functional excipient systems could capture value through formulation support, not only ingredient sales. The strongest position would combine excipient supply with process parameters, analytical methods, and technical transfer support.

What manufacturing and intellectual-property barriers affect entry?

Softgel entry requires equipment and process controls that tablet manufacturers may not possess. Key barriers include:

• Rotary-die encapsulation equipment.
• Controlled gelatin mass preparation.
• Accurate liquid-fill dosing.
• In-line leak and weight inspection.
• Drying and curing capacity.
• Shell-fill compatibility testing.
• Stability testing under ICH conditions.
• Packaging with suitable moisture and oxygen barriers.
• FDA-compliant quality systems and supplier qualification.

Manufacturing know-how can remain commercially valuable even when broad patents have expired. Critical trade secrets may include gelatin hydration timing, fill temperature, deaeration, die-roll settings, drying humidity, and rejection thresholds.

Which companies compete in the ibuprofen softgel market?

Competition includes branded products from Haleon, which markets Advil, private-label retailers, generic-drug manufacturers, and contract softgel producers. Major commercial competitors do not need to duplicate the Advil formulation. They can compete through price, capsule count, retailer exclusivity, packaging, dosage-form variants, or a different excipient system.

The competitive landscape is fragmented because ibuprofen is widely available. Brand strength matters most in analgesic aisle placement, advertising, consumer trust, and retailer relationships. Formulation differentiation must be visible to consumers or create measurable manufacturing savings to support a premium.

What generic launch scenarios exist for ibuprofen liquid-filled capsules?

Low-cost private-label launch

A retailer or generic manufacturer uses a conventional 200 mg ibuprofen liquid-filled capsule and competes on price. This is the lowest technical-risk scenario but faces margin pressure and limited brand differentiation.

Premium softgel launch

The product emphasizes easy swallowing, rapid release, vegetarian shells, or packaging convenience. This approach requires substantiation and stronger consumer marketing.

Pediatric or family-product launch

The sponsor uses smaller capsules, age-specific packaging, or a separate liquid dosage form. FDA labeling and safety considerations become more complex, especially for children under the labeled age range.

Combination-product launch

Ibuprofen is combined with another OTC active ingredient. The opportunity is larger basket value, but formulation compatibility, dose limits, labeling, and monograph compliance increase the regulatory burden.

What is the revenue exposure for Advil Liqui-Gels?

Public sources do not provide a product-level revenue figure for Advil Liqui-Gels. Haleon reports financial performance at broader category and brand levels rather than disclosing a separate audited revenue line for each Advil dosage form.[6]

Revenue exposure is therefore best assessed through retail scanner data, unit velocity, average selling price, distribution, promotional spending, and the share of Advil sales attributable to liquid-filled capsules. The product’s economic sensitivity is likely tied to:

• Premium price versus standard ibuprofen tablets.
• Brand share within the U.S. OTC analgesics category.
• Retailer private-label substitution.
• Consumer preference for softgels.
• Advertising and promotional intensity.
• Supply continuity for gelatin, polyethylene glycol, and packaging components.

Key Takeaways

• Advil Liqui-Gels is a 200 mg ibuprofen liquid-filled softgel regulated as an OTC analgesic product.
• Public labeling identifies polyethylene glycol, potassium hydroxide, sorbitol, gelatin, purified water, lecithin, colorant, and pharmaceutical ink among the inactive ingredients.
• The commercial advantage is dosage-form convenience and brand equity, not active-ingredient exclusivity.
• The most valuable technical variables are fill solubility, viscosity, alkalinity, shell integrity, dissolution, and moisture control.
• Paragraph IV litigation is generally not the central entry pathway for an OTC monograph ibuprofen softgel.
• New commercial opportunities include private-label products, vegetarian shells, rapid-release systems, pediatric formats, combination products, and sustainable packaging.
• The main barriers are softgel manufacturing capability, formulation know-how, quality systems, packaging performance, and brand-related intellectual property.
• Product-level Advil Liqui-Gels revenue is not separately disclosed in public Haleon reporting.

FAQs About Advil Liqui-Gels Excipients and Commercialization

Can polyethylene glycol be replaced in an ibuprofen softgel?

Yes. Potential alternatives include different polyethylene glycol grades, other pharmaceutical liquid vehicles, or modified ibuprofen salt systems. Replacement requires testing for solubility, viscosity, chemical stability, shell compatibility, dissolution, and shelf life.

Are Advil Liqui-Gels vegetarian?

The public U.S. ingredient listing identifies gelatin, so the standard U.S. Advil Liqui-Gels product is not a vegetarian softgel. A competing product could use a non-gelatin shell, but it would need separate performance and stability validation.

Can a generic company copy the Advil Liqui-Gels formulation?

A generic company can market a compliant ibuprofen softgel without copying the brand’s exact formulation. It must avoid applicable patent claims, trademarks, trade dress, and confidential manufacturing information while meeting FDA requirements.

Does a liquid-filled ibuprofen capsule necessarily work faster than a tablet?

No. A liquid fill may support faster dispersion or dissolution, but actual onset depends on the complete formulation, capsule shell, gastric conditions, dose, and pharmacokinetics. “Fast” performance requires product-specific testing.

Is Advil Liqui-Gels protected by a current patent?

The brand does not create a single current patent term. Historical softgel and ibuprofen formulation patents may have expired, while specific later patents, trademarks, manufacturing rights, or proprietary know-how could still affect a particular competitor’s freedom to operate.

References

1. Haleon. (n.d.). Advil Liqui-Gels 200 mg ibuprofen liquid-filled capsules: Drug facts label. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Ibuprofen drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. § 343. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (2022). Nonprescription drug products: Drug facts labeling. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/

6. Haleon plc. (2024). Annual report and financial statements 2023. https://www.haleon.com/insights/annual-report/